News
Events
Overview
Rationale for Immunodrugs™
Strategy
Board & Management
Industry Collaborations
Letter of the CEO
History
Overview
Immunodrug™ Platform
Immunodrug™ Manufacturing
Human Monoclonal Antibodies
Scientific Collaborations
Scientific Publications
Pipeline
Clinical Trials
Disease Areas
Overview
Ad-hoc Releases
Board & Management
Share Information
Bond Information
Analyst Coverage
Financial Calendar
Financial Reports
Corporate Governance
Stay Informed
Contact
Overview
Press Release Archive
Downloads
Picture Gallery
Contact
Preventing Chronic Diseases
– a Vital Investment
Cytos
Ad-hoc Releases
 
Cytos
Facts & Figures
 
Cytos Biotechnology AG
Wagistrasse 25
Postfach
8952 Schlieren
Switzerland
T +41 44 733 47 47
F +41 44 733 47 40
e-mail contact

Novel vaccines for chronic disease treatment and prevention

Cytos Biotechnology is dedicated to the discovery, development and commercialization
of a novel class of medicines – called Immunodrugs™. Immunodrugs™ are therapeutic
vaccines intended for use in the treatment and prevention of common chronic diseases
which afflict millions of people worldwide.

Important legal information: please read the disclaimer before proceeding.
News
Annual Report 2008 now available
  
2009, June 24: 
Cytos Biotechnology reports biochemical findings from phase IIa study with hypertension vaccine CYT006-AngQb.
 
 
2009, June 11: 
Cytos Biotechnology initiates combined phase I/IIa study with a
novel anti-interleukin-1 beta vaccine in patients with type II
diabetes mellitus.  
 
 
2009, May 7: 
Information relating to the
VLP influenza vaccine.